Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.70 USD
Change Today +0.31 / 1.89%
Volume 19.3K
DPRX On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

dipexium pharmaceuticals inc (DPRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - $17.10
52 Week Low
08/13/14 - $8.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

dipexium pharmaceuticals inc (DPRX) Related Businessweek News

No Related Businessweek News Found

dipexium pharmaceuticals inc (DPRX) Details

Dipexium Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibiotics for the treatment of infectious diseases. It develops Locilex (pexiganan cream 0.8%), a novel, broad spectrum, and topical antibiotic, which is in phase 3 clinical trials for the treatment of mild infections of diabetic foot ulcers. The company was founded in 2010 and is based in New York, New York.

5 Employees
Last Reported Date: 03/23/15
Founded in 2010

dipexium pharmaceuticals inc (DPRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $464.2K
Co-Founder and Executive Chairman
Total Annual Compensation: $364.2K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.8K
Chief Accounting Officer and Treasurer
Total Annual Compensation: $138.8K
Compensation as of Fiscal Year 2014.

dipexium pharmaceuticals inc (DPRX) Key Developments

Dipexium Eyes Acquisitions

Dipexium Pharmaceuticals, Inc. (NasdaqCM:DPRX) is looking for acquisition opportunities. Dipexium has filed a shelf registration in the amount of $100 million. Dipexium intend to use any net proceeds from the sale of securities under this prospectus for our operations and for other general corporate purposes, including, but not limited to, our internal research and development programs and the development of new programs, general working capital and possible future acquisitions.

Dipexium Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Dipexium Pharmaceuticals, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, the company reported a net loss of approximately $4,187,233, compared to $2,543,839 for the three months ended March 31, 2014, an increase of $1.7 million, primarily due to a $1.8 million increase in expenses related to stock option grants, partially offset by a decrease in research and development expenses of $0.1 million. Net cash used in operating activities for the three months ended March 31, 2015 was $3.0 million. Loss from operations was $4,187,233 compared to $2,543,839 a year ago. Basic and diluted net loss per common share/units was $0.49 compared to $0.44 a year ago.

Dipexium Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 14, 2015

Dipexium Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 7:30 AM, US Eastern Standard Time on May 14, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DPRX:US $16.70 USD +0.31

DPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DPRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation DPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIPEXIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at